Literature DB >> 20659488

Serotonin transporter gene-linked polymorphic region (5-HTTLPR) influences decision making under ambiguity and risk in a large Chinese sample.

Qinghua He1, Gui Xue, Chuansheng Chen, Zhonglin Lu, Qi Dong, Xuemei Lei, Ni Ding, Jin Li, He Li, Chunhui Chen, Jun Li, Robert K Moyzis, Antoine Bechara.   

Abstract

Risky decision making is a complex process that involves weighing the probabilities of alternative options that can be desirable, undesirable, or neutral. Individuals vary greatly in how they make decisions either under ambiguity and/or under risk. Such individual differences may have genetic bases. Based on previous studies on the genetic basis of decision making, two decision making tasks [i.e., the Iowa Gambling Task (IGT) and Loss Aversion Task (LAT)] were used to test the effect of 5-HTTLPR polymorphism on decision making under ambiguity and under risk in a large Han Chinese sample (572 college students, 312 females). Basic intelligence and memory tests were also included to control for the influence of basic cognitive abilities on decision making. We found that 5-HTTLPR polymorphism significantly influenced performance in both IGT and LAT. After controlling for intelligence and memory abilities, subjects homozygous for s allele had lower IGT scores than l carriers in the first 40 trials of the IGT task. They also exhibited higher loss aversion than l carriers in the LAT task. Moreover, the effects of 5-HTTLPR were stronger for males than for females. These results extend the literature on the important role of emotion in decision making under ambiguity and risk, and shed additional lights on how decision making is influenced by culture as well as sex differences. Combining our results with existing literature, we propose that these effects might be mediated by a neural circuitry that comprises the amygdala, ventromedial prefrontal cortex, and insular cortex. Understanding the genetic factors affecting decision making in healthy subjects may allow us to better identify at-risk individuals, and better target the development of new potential treatments for specific disorders such as schizophrenia, addiction, and depression.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659488      PMCID: PMC2946467          DOI: 10.1016/j.neuropharm.2010.07.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  71 in total

Review 1.  Pathological gambling: a comprehensive review of biobehavioral findings.

Authors:  Anna E Goudriaan; Jaap Oosterlaan; Edwin de Beurs; Wim Van den Brink
Journal:  Neurosci Biobehav Rev       Date:  2004-04       Impact factor: 8.989

2.  Planning, decision-making and the COMT rs4818 polymorphism in healthy males.

Authors:  Panos Roussos; Stella G Giakoumaki; Stefanos Pavlakis; Panos Bitsios
Journal:  Neuropsychologia       Date:  2007-10-22       Impact factor: 3.139

3.  Influence of BDNF and COMT polymorphisms on emotional decision making.

Authors:  Jee In Kang; Kee Namkoong; Ra Yeon Ha; Kyungun Jhung; Yang Tae Kim; Se Joo Kim
Journal:  Neuropharmacology       Date:  2010-02-12       Impact factor: 5.250

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Major depressive disorder, serotonin transporter, and personality traits: why patients use suboptimal decision-making strategies?

Authors:  Anita Must; Anna Juhász; Agnes Rimanóczy; Zoltán Szabó; Szabolcs Kéri; Zoltán Janka
Journal:  J Affect Disord       Date:  2007-03-26       Impact factor: 4.839

6.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

7.  Gene-gene interaction associated with neural reward sensitivity.

Authors:  Juliana Yacubian; Tobias Sommer; Katrin Schroeder; Jan Gläscher; Raffael Kalisch; Boris Leuenberger; Dieter F Braus; Christian Büchel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-02       Impact factor: 11.205

8.  Serotonin transporter genetic variation and the response of the human amygdala.

Authors:  Ahmad R Hariri; Venkata S Mattay; Alessandro Tessitore; Bhaskar Kolachana; Francesco Fera; David Goldman; Michael F Egan; Daniel R Weinberger
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Variation in dopamine genes influences responsivity of the human reward system.

Authors:  Jean-Claude Dreher; Philip Kohn; Bhaskar Kolachana; Daniel R Weinberger; Karen Faith Berman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-22       Impact factor: 11.205

10.  Exploring the neurological substrate of emotional and social intelligence.

Authors:  Reuven Bar-On; Daniel Tranel; Natalie L Denburg; Antoine Bechara
Journal:  Brain       Date:  2003-05-21       Impact factor: 13.501

View more
  36 in total

1.  Maladaptive decision making and substance use outcomes in high-risk individuals: preliminary evidence for the role of 5-HTTLPR variation.

Authors:  Jessica W O'Brien; Sarah D Lichenstein; Shirley Y Hill
Journal:  J Stud Alcohol Drugs       Date:  2014-07       Impact factor: 2.582

2.  Haplotype polymorphism in the alpha-2B-adrenergic receptor gene influences response inhibition in a large Chinese sample.

Authors:  Xuemei Lei; Chuansheng Chen; Qinghua He; Robert Moyzis; Gui Xue; Chunhui Chen; Zhongyu Cao; Jin Li; He Li; Bi Zhu; Mingxia Zhang; Jun Li; Qi Dong
Journal:  Neuropsychopharmacology       Date:  2012-01-04       Impact factor: 7.853

3.  Risk-seeking for losses is associated with 5-HTTLPR, but not with transient changes in 5-HT levels.

Authors:  Philipp T Neukam; Nils B Kroemer; Yacila I Deza Araujo; Lydia Hellrung; Shakoor Pooseh; Marcella Rietschel; Stephanie H Witt; Uwe Schwarzenbolz; Thomas Henle; Michael N Smolka
Journal:  Psychopharmacology (Berl)       Date:  2018-05-05       Impact factor: 4.530

4.  The neuroanatomical basis of the Gambler's fallacy: A univariate and multivariate morphometric study.

Authors:  Xiaolu Huang; Hanqi Zhang; Chuansheng Chen; Gui Xue; Qinghua He
Journal:  Hum Brain Mapp       Date:  2018-10-11       Impact factor: 5.038

Review 5.  A somatic marker perspective of immoral and corrupt behavior.

Authors:  Mona Sobhani; Antoine Bechara
Journal:  Soc Neurosci       Date:  2011-09-15       Impact factor: 2.083

6.  5-HTTLPR moderates the association between interdependence and brain responses to mortality threats.

Authors:  Siyang Luo; Dian Yu; Shihui Han
Journal:  Hum Brain Mapp       Date:  2017-09-17       Impact factor: 5.038

7.  Decoding the neuroanatomical basis of reading ability: a multivoxel morphometric study.

Authors:  Qinghua He; Gui Xue; Chunhui Chen; Chuansheng Chen; Zhong-Lin Lu; Qi Dong
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

8.  Serotonin transporter polymorphism (5-HTTLPR) in Croatian population.

Authors:  Jelena Culej; Mario Štefanović; Ivana Ćelap; Nora Nikolac; Dalibor Karlović
Journal:  Mol Biol Rep       Date:  2014-11-06       Impact factor: 2.316

Review 9.  A Neurobehavioral Approach to Addiction: Implications for the Opioid Epidemic and the Psychology of Addiction.

Authors:  Antoine Bechara; Kent C Berridge; Warren K Bickel; Jose A Morón; Sidney B Williams; Jeffrey S Stein
Journal:  Psychol Sci Public Interest       Date:  2019-10

10.  COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users.

Authors:  Antonio Verdejo-García; Ana Beatriz Fagundo; Aida Cuenca; Joan Rodriguez; Elisabet Cuyás; Klaus Langohr; Susana de Sola Llopis; Ester Civit; Magí Farré; Jordi Peña-Casanova; Rafael de la Torre
Journal:  Neuropsychopharmacology       Date:  2013-02-28       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.